At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 250 enrolled
Drug / intervention
Daptomycin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Aug 18, 2011·Updated Sep 5, 2018
In Brief
A Phase 4 clinical trial evaluating Daptomycin and Vancomycin for Staphylococcal Skin Infections. Completed, enrolled 250 participants across 26 sites in 2 countries.
Detailed Summary
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin. The purpose of this study is to compare infection-related hospital length of stay, along with a number of participant-reported outcomes, between participants with complicated skin and soft tissue infection treated with daptomycin and vancomycin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStaphylococcal Skin Infections
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartSep 2011
Primary CompletionSep 2012
Study CompletionOct 2012
TodayJul 2026
First PostedAug 18, 2011
Enrollment StartSep 9, 2011
Primary CompletionSep 1, 2012
Study CompletionOct 5, 2012
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 14.9 years ago
Interventions
Daptomycindrug
Vancomycindrug